LOTRISONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOTRISONE (LOTRISONE).
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
| Metabolism | Clotrimazole is primarily metabolized in the liver via oxidation and glucuronidation; betamethasone is metabolized in the liver via CYP3A4. |
| Excretion | Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites). |
| Half-life | Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis. |
| Protein binding | Clotrimazole: 90-95% bound to plasma proteins; betamethasone: approximately 64% bound (primarily to albumin and corticosteroid-binding globulin). |
| Volume of Distribution | Clotrimazole: negligible systemic Vd due to minimal absorption; betamethasone: 1.4 L/kg (large distribution, high tissue penetration). |
| Bioavailability | Topical: minimal systemic absorption (clotrimazole <0.5%, betamethasone dipropionate <5% of dose); not formulated for oral use. |
| Onset of Action | Topical: clinical improvement often noted within 1 week of twice-daily application. |
| Duration of Action | Topical: applied twice daily; clinical cure rates high after 2 weeks of treatment; duration limited by application schedule. |
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment based on Child-Pugh score. |
| Pediatric use | Apply a thin film to affected areas twice daily for 2 weeks. Not recommended for children under 2 years of age. Safety and efficacy in pediatric patients have not been established beyond 2 weeks of use. |
| Geriatric use | Use with caution due to increased risk of skin atrophy and systemic absorption. Limit treatment duration to 2 weeks. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOTRISONE (LOTRISONE).
| Breastfeeding | Lotrisone is applied topically with minimal systemic absorption. Both clotrimazole and betamethasone are excreted in breast milk in low amounts if absorbed systemically. However, topical application to small areas unlikely results in significant milk levels. M/P ratio: Not established for topical use; for systemic betamethasone, M/P ratio ~0.3. Use caution to avoid application to breast area to minimize infant ingestion. Generally considered compatible with breastfeeding if used short-term on limited areas. |
| Teratogenic Risk | Lotrisone (clotrimazole/betamethasone dipropionate) is a topical corticosteroid/antifungal combination. Systemic absorption is minimal after topical application. Animal studies with topical corticosteroids have shown teratogenicity, but no controlled human data exist. The risk is considered low with proper use, especially in the first trimester. In the second and third trimesters, avoid prolonged or widespread use. Corticosteroids may cause intrauterine growth restriction if significant systemic absorption occurs. Overall, fetal risk is low with limited cutaneous application. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to betamethasone dipropionate, clotrimazole, or any component of the formulation.","Ophthalmic use (not for use in the eyes)."]
| Precautions | ["Topical corticosteroids may cause reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.","Systemic absorption may be increased with use on large surface areas, prolonged use, occlusive dressings, or in pediatric patients.","Local adverse reactions include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.","Concomitant skin infections should be treated with appropriate antimicrobial therapy."] |
Loading safety data…
| Fetal Monitoring | No specific routine fetal monitoring required for typical use. For prolonged or widespread use (especially of high-potency corticosteroid component), consider monitoring for signs of maternal adrenal suppression, fetal growth restriction, and preterm labor. Use intermittent fetal monitoring if prolonged therapy on large surface areas is necessary. Assess maternal blood pressure and blood glucose if significant systemic absorption suspected. |
| Fertility Effects | No known adverse effects on male or female fertility from topical application of Lotrisone. Systemic corticosteroids may affect ovulation or sperm parameters at high doses, but topical use does not produce such levels. No specific fertility monitoring is required. |